Harrow jumps on predicting Q4 sales above estimate
Harrow HROW.O soars ~24% to $28.90 premarket
Eye-drug maker sees prelim Q4 sales in the $65 mln-$67 mln range; analysts' estimate stands at $58.4 mln, per data compiled by LSEG
Forecasts 2025 sales to be more than $280 mln, slightly below analysts' estimate of $281.2 mln
Expects its FDA-approved, high-profit branded products to be the main driver of growth this year
HROW gained ~181% in 2024
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Robinhood Slumps 8% After Earnings. Revenue and Profit Both Miss, Market Fears Coinbase May Follow Suit.

GOOGL Vs. MSFT: 2 Monster Stocks to Hold for the Next 5 Years

Tradingkey







